Paris-based Stentys takes $18M for “bifurcated” stents — Stentys, a Paris-based medical device maker, raised $18 million in a second funding round. The company is developing “bifurcated” stents intended to prop open clogged arteries at blood-vessel junctions.
The startup said the funding will allow it to complete clinical trials of its stents and to win European regulatory approval for them. Stentys doesn’t seem to have given any indication whether or when it might seek approval in the U.S. or other markets as well.
Scottish Equity Partners and Sofinnova Partners provided the funding.
Blood analyzer IntelliDx raises $22M —It’s starting to look like Diabetes Week here at VentureBeat LifeScience.
IntelliDx (no Web site), a Boston Santa Clara, Calif., startup with a new type of blood-sugar analyzer for hospitalized diabetics, raised $21.5 million in a fourth funding round (PDF link). Investors included HLM Venture Partners, 3i Ventures, Giza Ventures, Ascend Ventures, Aurum Ventures, Sequel Venture Partners and Hunt BioVentures.
IntelliDx makes a chemical sensor-based blood analyzer for use in hospital intensive-care units. Much like the Luminous Medical spectroscopic blood-glucose analyzer we covered yesterday, the IntelliDx device aims to monitor blood sugar hourly in diabetic patients. The idea, again, is to keep a closer eye on hyperglycemia in a critical-care setting, since runaway blood glucose often increases the chance of complications and lengthier hospital stays.
Cancer-test biotech Calderome changes name to VeraCyte — Calderome, a stealthy cancer-test startup in South San Francisco, has changed its name to VeraCyte (no Web site), VentureWire reports. The new name presumably reflects the company’s focus on cell-based cancer diagnostics, as we described last week.
The VentureWire story goes on to reprise VeraCyte’s $12 million fundraising, which we also covered last week. VeraCyte has two employees, and recently extended job offers to three other individuals, the news service reported.
CORRECTED: The IntelliDx item initially located the company in Boston, not Santa Clara. The company’s release was datelined Boston because it originated with HLM Ventures. Apologies for the error.
